Log In
Print
BCIQ
Print
Print this Print this
 

SynCon DNA prostate cancer vaccine (INO-5150)

  Manage Alerts
Collapse Summary General Information
Company Inovio Pharmaceuticals Inc.
DescriptionDual-antigen DNA prostate cancer vaccine targeting PSA and PSMA synthetic consensus immunogens based on human and monkey sequences
Molecular Target Prostate-specific antigen (KLK3) (PSA) ; Prostate-specific membrane antigen (PSMA) (FOLH1) (GCPII)
Mechanism of Action 
Therapeutic ModalityPreventive vaccine: DNA vaccine
Latest Stage of DevelopmentPreclinical
Standard IndicationProstate cancer
Indication DetailsTreat prostate cancer
Regulatory Designation

Partner


 Product Details
 Archive Items are loading loading
Collapse Summary Deals Information
Total Number of DealsTotal Deal ValueTotal Upfront CashTotal Milestone Payments

1

$422.5M

0

0


 Deals Details
DateCompanies InvolvedDeal HeadlineTotal Deal ValueTotal Upfront CashTotal Milestone
Get a free BioCentury trial today